BUSINESS

Otsuka’s Therapeutic App for Depression Now Available in Great Britain

June 18, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Otsuka Pharmaceutical and Click Therapeutics said on June 17 that their prescription smartphone app Rejoyn has been launched in Great Britain for the treatment of major depressive disorder (MDD). This marks the product’s second global rollout after its debut in…

To read the full story

Otsuka Rolls Out Therapeutic App for Depression in US
August 19, 2024
FDA OKs First Digital Therapeutic App for Depression: Otsuka
April 4, 2024

BUSINESS

Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
March 6, 2026
Japan Grants First-Ever Approval to iPSC-Based Therapies
March 6, 2026
Meiji Starts Japan PIII Trial of Rezurock for CLAD
March 6, 2026
Meiji Rolls Out Rezurock in Taiwan
March 6, 2026
Toray Out-Licenses Parkinson’s Drug to Immunis
March 6, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…